EUCTR2019-003656-37-ES进行中（未招募）1 期
A randomized, double-blind, placebo-controlled, parallel arm group study to evaluate the analgesic efficacy and safety of dexketoprofen trometamol and tramadol hydrochloride oral fixed dose combination on moderate to severe acute pain in patients with acute low back pain – DANTE study - DANTE
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 538
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Properly executed written informed consent.
- •2. Male or female patients aged 18 years to 65 years.
- •3. Patients with acute low back reporting pain of at least moderate intensity at Screening (NRS score = 5). The onset of the current acute low back pain episode is within 48 hours prior to Screening.
- •4. Patients with or without radiculopathy will be included, excluding those with neurological signs, according to the Quebec Task Force classification.
- •5. Naïve patients to any low back pain or patients with previous history of low back pain experiencing a new episode, preceded by a period of at least 2 months without any low back pain prior to Screening.
- •6. Patients free from analgesic (as per exclusion criterion 14) due to previously administered pain killer (immediate or slow release formulations), according to physician’s judgment.
- •7. Females participating in the study must be either:
- •- Females of nonchildbearing potential, defined as any woman who had undergone surgical sterilization (documented hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or is more than 2 years postmenopausal (defined as no menses for 12 months);
- •- Females of childbearing potential (following menarche until menopause unless permanently sterile) provided that they have a negative pregnancy test at Screening and are routinely using an effective method of birth control resulting in a low failure rate (ie, combined hormonal contraception, intrauterine device, condoms in combination with a spermicidal cream, male partner sterilization (vasectomy), bilateral tubal occlusion or total sexual abstinence) during the study treatment.
- •8. Mentally competent and able to understand and give written informed consent prior to Screening.
- •9. Compliant to undergo all visits and procedures scheduled in the Study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 667
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 13
排除标准
- •1. Patients who are judged by the Investigator not to be suitable candidates for the study treatments and the RM based on their medical history, physical examination, CM and concurrent systemic diseases.
- •2. Clinically significant abnormalities in the vital signs as per Investigator’s judgment.
- •3. Patients with acute low back pain and radiation to limb with presence of neurologic signs (focal weakness, asymmetry of reflexes, sensory loss in a dermatome, or loss of bowel, bladder, or sexual function) according to Quebec Task Force Classification.
- •4. History of hypersensitivity to the study treatments, RM or to any other nonsteroidal anti-inflammatory drugs (NSAIDs), or opioids.
- •5. Known photoallergic or phototoxic reactions during treatment with ketoprofen or fibrates.
- •6. History of peptic ulcer, gastrointestinal disorders when taking NSAIDs, gastrointestinal bleeding, or other active bleeding.
- •7. History of allergy (eg, precipitate attacks of asthma, bronchospasm, acute rhinitis, or cause nasal polyps, urticaria or angioneurotic oedema) to the study treatments, RM or to any other NSAIDs, or opioids.
- •8. Anamnestic mild to severe renal dysfunction, mild to severe hepatic dysfunction, as per Investigator’s judgment.
- •9. Patients with chronic dyspepsia.
- •10. Patients with severe heart failure (Class III and Class IV of New York Heart Association [NYHA] Classification).
- •11. History of hemorrhagic diathesis and other coagulation disorders.
- •12. History of or current epilepsy or convulsions.
- •13. Patients with Crohn’s disease or ulcerative colitis.
- •14. Patients receiving monoamine oxidase (MAO) inhibitors (a minimum of 14 days of washout must elapse prior to the Screening).
- •15. Treatment with topical preparations/medications within 4 hours prior to Screening, anesthetics and muscle relaxants within 8 hours prior to Screening, short-acting analgesics (eg, paracetamol) within 4 hours prior to Screening, other analgesics within 5 half-lives prior to Screening or use of an opioid within the 14 days preceding Screening.
- •16. Treatment with high doses of salicylates (=3 g/day), anticoagulants, thrombolytic and antiplatelet agents, heparins, corticosteroids (except inhalers and topical agents), lithium methotrexate, used at high doses of 15 mg/week or more, hydantoins (including phenytoin) and sulphonamides, antiepileptics, antipsychotics, serotonin reuptake inhibitors and tricyclic antidepressants, and analgesics within 48 hours or 5 half-lives (whichever is the longer) prior to Screening.
- •17. Patients using sedatives (eg, benzodiazepines) and hypnotic agents within 8 hours before Screening.
- •18. Any chronic or acute painful condition other than the study indication that may interfere with the assessment of the efficacy of the study treatment.
- •19. Any non-pharmacological interventional therapy for low back pain (physical therapy, acupuncture, massage etc.) one month before Screening.
- •20. Patients with litigation related to work.
- •21. Patients with severe dehydration (caused by vomiting, diarrhea, or insufficient fluid intake) within one month prior to Screening.
- •22. Severe respiratory depression according to physician’s judgment.
- •23. Participation in other clinical studies in the previous 4 weeks.
- •24. History of drug or alcohol abuse. For the purpose of the study, alcohol abuse is defined as regularly intake of more than 4 units of alcohol per day (1 unit corresponds approximately to 125 ml wine, 200 ml beer, 25 ml spirit).
- •25. History of any illness or co
研究者
相似试验
进行中（未招募）
Unknown
actoSpore® as an adjuvant in the treatment of Bacterial VaginosisCTRI/2023/05/052560Sami Sabinsa Group Limited
进行中（未招募）
1 期
Efficacy and safety of dexketoprofen trometamol and tramadol hydrochloride combination on moderate to severe acute pain in patients with acute low back paiow back painMedDRA version: 21.0Level: LLTClassification code 10024891Term: Low back painSystem Organ Class: 100000004859EUCTR2019-003656-37-HRMenarini International Operations Luxembourg SA510
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, parallel group study to investigate the safety and tolerability of 14-days treatment with an inhaled dose of QMF149 (500/800) in mild to moderate asthmatic patients.asthmaEUCTR2007-004608-11-FRovartis Pharma Services AG28
已完成
不适用
Boswellia serrata extract 200 mg capsules in subject with Irritable Bowel Syndrome.CTRI/2019/11/022190Inventia Healthcare Limited50
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, parallel group study to evaluate the effects of a 4-week treatment of 30 mg b.i.d BIBW 2948 BS (inhalation powder, hard capsule for HandiHaler®) on epithelial mucin stores and the safety and efficacy in COPD patients with symptoms associated with chronic bronchitis - Effects of BIBW 2948 on epithelial muciEUCTR2006-001975-40-IEBoehringer Ingelheim Limited60